Directorate Change

RNS Number : 7806M

Epistem Holdings plc

11 May 2015

 

Directorate changes

11^th May 2015

Further to the announcement on 24 November 2014 advising of Dr Ian Gilham's appointment as a non-executive Director and Chairman designate, Epistem Holdings Plc (LSE: EHP, "Epistem" or "the Company"), the personalised medicine and biotechnology company, announces that Dr Ian Gilham has today been appointed as non-executive Chairman of Epistem, succeeding David Evans who also today retires as a Director of the Company.

David Evans has played a key role in the development of the Company since his appointment as a Director in 2005. He was appointed executive Chairman in March 2006, becoming non-executive Chairman on the Company's admission to AIM in April 2007.

Commenting on his retirement from the Company, David Evans said: "After ten years in office, it is right that I stand down as Chairman of the Company and I am very pleased to be able to hand on the baton to Dr Ian Gilham who has extensive experience of the diagnostics industry. I would like to express my thanks to the Board and all the staff of Epistem for the support I have received over the last ten years and extend my best wishes to all concerned as the Company develops its novel technology in the rapidly expanding point of care molecular diagnostics market."

Matthew Walls, Chief Executive Officer, said: "On behalf of the Company, I reiterate my thanks to David Evans for his exemplary chairmanship and absolute commitment to Epistem over the past decade as Epistem has established itself on AIM. His contribution and conduct has been an inspiration to us all. Weare also delighted to welcome as Chairman Ian Gilham who, since his appointment as Director in November 2014, has assisted with our gaining Indian regulatory approval for the launch of Genedrive^® our first molecular point of care diagnostic product."

For further details please see contact:

Epistem Holdings Plc

Matthew Walls: Chief Executive Officer                                                         ++44 (0)161 606 7258

John Rylands: Finance Director

Peel Hunt LLP

James Steel                                                                                                           ++44 (0)207 418 8900

Clare Terlouw

Walbrook PR

Mike Wort                                                                                                             ++44 (0)207 933 8780

Anna Dunphy

Please see http://www.epistem.co.ukfor additional information.

Notes to Editors:

About Epistem

Epistem (http://www.epistem.co.uk) is a personalised medicine and biotechnology company commercialising its technology and expertise in the areas of infectious and epithelial disease (oncology, gastrointestinal and dermatological). Epistem develops innovative diagnostics and pharmacogenomics (Genedrive^®), target discovery of novel therapeutics and contract research services for drug development companies. Epistem operates three divisions, Personalised Medicine (Diagnostics and Pharmacogenomics), Contract Research Services and Novel Therapies.

Genedrive® (http://www.genedrive.com) provides a major advance in next-generation molecular diagnostic testing by providing a handheld, rapid, low-cost, simple-to-use 'point of care' device with high sensitivity and specificity for diagnosis of infectious diseases. Genedrive® aims to provide a 'gold standard' identification of tuberculosis and antibiotic resistance. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs.

Epistem's Genedrive®platform has applications across a wide range of bacterial, viral and fungal and somatic mutation diseases for which Epistem is developing a menu of diagnostic tests.

 

END

 

 

BOAGGUPAAUPAGUG